Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors

• DOI: 10.3389/fcvm.2022.916085
• Publication Date: 2022-07-27T05:19:09Z
• Authors: Le Wang; Hong-liang Cong; Jing-xia Zhang; Xi-ming Li; Yue-cheng Hu; Chen Wang; Jia-chun Lang; Bing-yang Zhou; Ting-ting Li; Chun-wei Liu; Hua Yang; Li-bin Ren; Wei Qi; Wen-yu Li
• Keywords: Mace

Acute coronary syndrome (ACS) without standard modifiable cardiovascular risk factors (SMuRFs) represents a special case of ACS. Multiple biomarkers have been shown to improve stratification in patients with However, the utility for prognostic ACS SMuRFs remains uncertain. The aim present study was evaluate value various patents SMuRFs.Data consecutive who underwent angiography Tianjin Chest Hospital between January 2014 and December 2017 were retrospectively collected. primary outcome occurrence major adverse event (MACE), defined as composite death, myocardial infarction stroke. Seven candidate analyses analyzed using models adjusted established factors.During median 5-year follow-up, 81 621 experienced MACE. After adjustment important covariates, elevated fibrinogen, D-dimer, N-terminal proB-type natriuretic peptide (NT-proBNP), lipoprotein (a) [Lp(a)] found be individually associated only NT-proBNP Lp(a) significantly improved reclassification MACE (all P < 0.05). multimarker analysis showed that there clear increase an increasing number higher score. hazard ratio- (95% confidential intervals) 4 6.008 (1.9650-18.367) relative those any biomarker-. Adding- or score basic model C-statistic value, net index integrated discrimination 0.05).Fibrinogen, provided valuable information when applied SMuRFs. strategy, which combined multiple reflecting different pathophysiological process traditional stratification.